There is also recent evidence from our group demonstrating that some melanomas with BRAF V600E mutations may be intrinsically resistant to inhibitors of BRAF as a result of cyclin D1 amplification (Smalley et al, 2008). The gene discussed is BRAF; the disease is melanoma.